SupplementDrug
VSL#3 clinical trials
- studies test it
- 47
- open now
- 3
- in phase 3
- 9
- first study started
- 2004
Keep track of what changes. Save the VSL#3 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
45 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 4 |
| 2010 | 5 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 4 |
| 2022 | 3 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 3
- Phase 1
- 4
- Phase 2
- 11
- Phase 3
- 9
- Phase 4
- 10
- No phase
- 17
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 42
VSL Pharmaceuticals (3) · University of Wisconsin, Madison (2) · Policlinico Hospital (2) · CD Pharma India Pvt. Ltd. (2) · Govind Ballabh Pant Hospital (2) · Hadassah Medical Organization (2) · Charles University, Czech Republic (1) · Assistance Publique - Hôpitaux de Paris (1)
Often tested with
Tested in the same studies.
AISA-5203 (1) · Argan oil (1) · Low FODMAP Diet (1) · Lactobacillus acidophilus DSM 24735 (1) · Lactiplantibacillus plantarum DSM 24730 (1) · Lacticaseibacillus paracasei DSM 24733 (1) · Lactobacillus delbrueckii bulgaricus DSM 24734 (1) · Streptococcus thermophilus DSM 24731 (1)
Studies
Open first, then newest update. How each study uses VSL#3 is read from its arms, and is right about nine times in ten.
Testing it · 47
- Intervention on New Onset-T1D ChildrenRecruitingNot applicableIRCCS San RaffaeleNCT05767450Written as Probiotic Vivomixx®
- The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative ColitisRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06609447Written as VSL#3
- VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)RecruitingNot applicableFondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoNCT05874089Written as VSL#3®
- The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel DiseaseActive, not recruitingNot applicableCharles University, Czech RepublicNCT01765439Written as VSL#3 (Original De Simone formulation)
- Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)CompletedNot applicableAssistance Publique - Hôpitaux de ParisNCT03092427Written as VSL#3
- Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving ImmunotherapySuspendedNot applicableMayo ClinicNCT06508034Written as Live Freeze-Dried Lactic Acid Bacteria Probiotic
- Modulation of Type 1 Diabetes Susceptibility Through the Use of ProbioticsCompletedNot applicableMedical College of WisconsinNCT03423589Written as VSL#3
- Impact of Probiotics on Oral Microbiota in Older Adults With DysphagiaCompletedEarly Phase 1University of Wisconsin, MadisonNCT03682094Written as VSL#3
- Safety of VSL#3 in Adult AsthmaticsTerminatedPhase 1/2University of Maryland, BaltimoreNCT00852124Written as VSL#3
- Ability of the Probiotic Vivomixx to Improve Environmental Enteropathy in Pregnant Women: a Proof of Concept Trial in Bangladesh, Pakistan, Senegal and ZambiaStatus unknownPhase 2Tropical Gastroenterology & Nutrition Group (TROPGAN)NCT05608928Written as VSL#3
- Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin SystemCompletedEarly Phase 1Göteborg UniversityNCT01635192Written as VSL#3
- Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to FibromyalgiaCompletedNot applicableElena Pita CalandreNCT04256785Written as VSL#3
- One Year Home Monitoring and Treatment of IBS PatientsStatus unknownNot applicableNordsjaellands HospitalNCT03586622Written as VSL#3®
- Effect of VSL#3 on Bone Mineral Density in Postmenopausal WomenTerminatedPhase 2Emory UniversityNCT03165747Written as VSL#3
- PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative ColitisTerminatedNot applicableVSL PharmaceuticalsNCT03415711Written as VSL#3®
- Dose Ranging Study With the Probiotic Combination (VSL#3) in Diarrhea IBSTerminatedNot applicableBeth Israel Deaconess Medical CenterNCT00179582Written as VSL#3
- Probiotic (VSL #3) for Gulf War IllnessTerminatedPhase 2/3University of UtahNCT02011542Written as VSL#3
- Probiotic (Visbiome) for Gulf War IllnessStatus unknownPhase 2/3Ashok TutejaNCT03078530Written as VSL#3
- Probiotics and the Gut Microbiome in Obese Hispanic YouthTerminatedNot applicableUniversity of Southern CaliforniaNCT03115385Written as VSL#3
- Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90°CompletedNot applicableBambino Gesù Hospital and Research InstituteNCT01650025Written as VSL#3 active probiotic
See all 47 studies that test VSL#3 →
Given in every arm · 2 — VSL#3 is usual care beside what is tested
- Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.CompletedNot applicableInstitute of Liver and Biliary Sciences, IndiaNCT01196481Written as Carvedilol+VSL#3
- Gastric Acid Suppression and Probiotic ColonizationCompletedPhase 4Stanford UniversityNCT03327051Written as VSL #3
Codes
What other systems call VSL#3 · ClinicalTrials.gg INT018010
- UNII (FDA) TC549UFL8PVSL#3One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TC549UFL8P | VSL#3 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.